Application of SLC2A3 in preparation of gastric cancer peritoneal metastasis diagnostic kit
By using SLC2A3 as a diagnostic marker for peritoneal metastasis of gastric cancer, a diagnostic kit for peritoneal metastasis of gastric cancer was developed, and SLC2A3 expression was inhibited through siRNA, solving the problem of diagnosis and treatment of peritoneal metastasis of gastric cancer, improving diagnostic accuracy and therapeutic effect.
Patent Information
- Application Number
- CN202411118701.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art has not yet effectively utilized SLC2A3 as a diagnostic marker for peritoneal metastasis in gastric cancer, and its specific relationship with ferrous death in gastric cancer is not clear, and there is a lack of diagnosis and treatment methods for peritoneal metastasis in gastric cancer.
Using SLC2A3 as a diagnostic marker for peritoneal metastasis in gastric cancer, a specific PCR primer and reverse transcription system was designed to develop a diagnostic kit for peritoneal metastasis in gastric cancer, using real-time quantitative PCR technology to detect the expression level of SLC2A3, and inhibit SLC2A3 by interfering RNA through siRNA. Expressed to inhibit gastric cancer cell migration.
It improves the detection rate and accuracy of peritoneal metastasis of gastric cancer, provides new diagnostic and treatment strategies, significantly inhibits the migration ability of gastric cancer cells, has high sensitivity and specificity, and fills the gap in the existing technology.
Smart Images

Figure CN118932059A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical biological detection technology, and particularly to the application of SLC2A3 as a molecular marker in gastric cancer diagnosis, and in particular to the application of SLC2A3 in the preparation of a diagnostic kit for gastric cancer peritoneal metastasis. Background Art
[0002] Gastric cancer is a gastrointestinal malignancy that accounts for 17.2% of all malignant tumors and has the second highest mortality rate among all common tumors worldwide. Due to the continuous improvement of medical diagnosis in recent years, the diagnosis rate of gastric cancer has also increased. Although medical advances have led to the development of gastric cancer treatment methods, the overall clinical treatment outcomes of gastric cancer are still poor. In recent years, with the continuous development and growth of molecular biology and genomics, screening for new prognostic markers has gradually become a new strategy to predict patient prognosis and also contribute to the treatment of cancer patients.
[0003] The SLC2A protein family consists of 14 proteins containing 12 transmembrane domains that catalytically facilitate the diffusion of glucose and other monosaccharides, and therefore these carrier proteins are central regulators of cellular energetics. High glucose transporter expression levels contribute to increased glucose uptake and oncogenic growth. SLC2A3 plays a crucial role in the development of gastric cancer by promoting glucose transport across the cell membrane, thereby supporting the enhanced glycolytic activity required for rapid proliferation of tumor cells. This abnormal metabolic behavior, characterized by increased glucose uptake, is an important hallmark of the development and progression of malignant tumors.
[0004] In a retrospective study, immunohistochemical staining of gastric cancer specimens from 150 patients who underwent total gastrectomy between 2005 and 2010 showed that the expression of Glut-1, Glut-3, Glut-6, and Glut-10 was associated with prognosis as well as clinical and pathological parameters. The expression rates of Glut-1, Glut-3, Glut-6, and Glut-10 in the 150 gastric cancer tissues were 22.0%, 66.0%, 38.0%, and 43.3%, respectively, but Glut-1, Glut-6, and Glut-10 were not associated with prognosis, and positive staining of Glut-3 was associated with higher UICC stage and worse prognosis. The mean overall survival of Glut-3-positive patients was 38.6 months, while that of Glut-3-negative patients was 51.2 months (p<0.05). Co-expression of two or more analyzed glucose transporters was associated with poor prognosis. Glut-3 and UICC stage were significant prognostic factors in multivariate analysis.
[0005] Compared with normal cells, the expression profile of SLC2A3 in tumor cells is significantly different, and it is involved in a variety of malignant biological behaviors such as tumor cell proliferation, invasion, and metastasis. Studies have confirmed that SLC2A3 can regulate the function of gastric cancer cells through a variety of mechanisms. SLC2A3 may promote gastric cancer cell proliferation by activating the phosphorylation of the STAT3 signaling pathway, and STAT3 may mediate SLC2A3 expression by binding to the SLC2A3 promoter region. Through the above mechanism, SLC2A3 affects the activation of the proliferation signaling pathway, thereby changing the biological state of the cell and affecting the occurrence and development of the tumor. However, the phenotypic relationship and mechanism of SLC2A3 and gastric cancer organ-specific peritoneal metastasis have not yet been clarified and need further exploration.
[0006] SLC2A3 is located at chr12:7,919,230-8,019,007, GENE ID 6515. SLC2A3 is a protein-coding gene. SLC2A3 is a ferroptosis gene that has been found to be highly expressed in gastric cancer, colon cancer, and other tumors. However, the specific relationship between SLC2A3 and ferroptosis in gastric cancer is still unknown and has not been studied in other tumor fields. The mechanism by which SLC2A3 promotes peritoneal metastasis of gastric cancer by reducing the occurrence of ferroptosis is also unknown.
[0007] There are very few studies on SLC2A3. This gene has 11 transcripts (splicing variants), 491 orthologs, and 13 paralogs. It is preferentially expressed in bone marrow (RPKM 183.0), placenta (RPKM 54.5), and 11 other tissues. Therefore, it is of great significance to find markers for peritoneal metastasis of gastric cancer and further understand the mechanism of SLC2A3 in peritoneal metastasis of gastric cancer from the perspective of ferroptosis. There is no literature report on the application of SLC2A3 in the diagnosis of gastric cancer. Summary of the invention
[0008] The purpose of the present invention is to provide a diagnostic marker for gastric cancer peritoneal metastasis. The purpose of the present invention is also to provide a new use of SLC2A3, namely, use in the preparation of a diagnostic kit for gastric cancer peritoneal metastasis.
[0009] In a first aspect, the present invention provides the use of SLC2A3 as a diagnostic marker for gastric cancer peritoneal metastasis.
[0010] The second aspect of the present invention provides the use of SLC2A3 in the preparation of a diagnostic reagent or a diagnostic kit for gastric cancer peritoneal metastasis.
[0011] Preferably, the diagnostic reagent is a reagent for detecting the content of SLC2A3 in a biological sample; the diagnostic kit comprises a reagent for detecting the content of SLC2A3 in a biological sample.
[0012] More preferably, the reagent for detecting the content of SLC2A3 in a biological sample is selected from PCR primers with detection specificity for SLC2A3.
[0013] The PCR primers with detection specificity for SLC2A3 are as follows:
[0014]
[0015] Preferably, the biological sample is selected from gastric cancer tissue of the test subject.
[0016] In a third aspect, the present invention provides a diagnostic kit for gastric cancer or gastric cancer peritoneal metastasis, the kit comprising a reagent for detecting the content of SLC2A3 in a biological sample.
[0017] Specifically, the diagnostic kit is composed of a reverse transcription system, a primer system and an amplification system, and the primer system includes the PCR primers shown in SEQ ID NO. 1-2 above.
[0018] A fourth aspect of the present invention provides a method for detecting peritoneal metastasis of gastric cancer using the above diagnostic kit, as follows:
[0019] A. Extract total RNA from gastric cancer tissues;
[0020] B. Reverse transcription of the total RNA in step A to obtain cDNA;
[0021] C. The copy number of SLC2A3 was quantitatively detected by real-time quantitative PCR technology. The primers used in the detection process are shown in SEQ ID NO: 1-2.
[0022] All data were processed using SPSS16.0 and expressed as mean ± standard deviation.
[0023] Experiments have shown that the expression level of SLC2A3 gene in gastric cancer tissue is higher than that in normal tissue; downregulating SLC2A3 expression can significantly inhibit the migration ability of gastric cancer cells, thereby achieving the effect of inhibiting gastric cancer; suggesting that SLC2A3 has a clear cancer-promoting biological function and can be used in the diagnosis of gastric cancer peritoneal metastasis or gastric cancer treatment.
[0024] The fifth aspect of the present invention provides the use of SLC2A3 in the preparation of a drug for treating gastric cancer.
[0025] The drug is an agent for inhibiting or silencing the expression of SLC2A3, specifically an interfering RNA of SLC2A3. In a preferred embodiment of the present invention, the sequence of the interfering RNA of SLC2A3 is shown in any one of SEQ ID NO.3 to 5, preferably the sequence shown in SEQ ID NO.3:
[0026] siRNA#1, tgtcactggtggctgctttat (SEQ ID NO.3);
[0027] siRNA#2,ccttcctgctatcctacaaag (SEQ ID NO.4);
[0028] siRNA#3, ccctccgctgctcactattta (SEQ ID NO. 5).
[0029] The beneficial protection and effects of the present invention are as follows:
[0030] In terms of technology, the detection of SLC2A3 is essentially a quantitative PCR test of organ tissues, which has the characteristics of simple operation, sensitive detection, good specificity and high repeatability. It has been increasingly used in clinical testing technology.
[0031] The basic detection method we use is RT-qPCR, which has been proven to be a highly sensitive and accurate detection method in modern laboratory diagnostics. The experimental technology is already very mature, and we use the standard curve quantification method in this technology, which can accurately quantify the characteristic nucleic acid molecules in various samples.
[0032] In addition, the expression of the indicator SLC2A3 involved in the present invention in gastric cancer tissue is significantly upregulated, and the difference is statistically significant (P<0.05), which can improve the detection rate and accuracy of gastric cancer peritoneal metastasis. It has high clinical reference value and credibility, and is an effective supplement to the current detection methods. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 The comparison of Glut-3 expression in gastric cancer and non-gastric cancer tissues is shown;
[0034] Figure 2 It was shown that the SLC2A3 gene is highly expressed in gastric cancer cells;
[0035] Figure 3 It showed that SLC2A3 expression was downregulated after transfection with specific siRNA;
[0036] Figure 4 It was shown that downregulating SLC2A3 expression could significantly inhibit the migration ability of gastric cancer cells. DETAILED DESCRIPTION
[0037] The present invention will now be described in detail in conjunction with the embodiments and drawings, but the implementation of the present invention is not limited thereto.
[0038] The reagents and raw materials used in the present invention are all commercially available or can be prepared according to literature methods. The experimental methods in the following examples where specific conditions are not specified are generally carried out according to conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to conventional conditions, or according to the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by volume.
[0039] Example 1 SLC2A3 is highly expressed in gastric cancer cells
[0040] 1. Cell culture
[0041] Human immortalized gastric epithelial cells GES-1, human gastric cancer cell lines MKN45, NCI-N87, HGC27, MKN7, Fu97 and MGC803 were cultured in a 37°C, 5% CO2 incubator using DMEM medium containing 10% fetal bovine serum.
[0042] 2. RNA Extraction
[0043] 1) Place the dish with cells on ice, wash twice with PBS, add 1 ml Trizol / dish, and pipette repeatedly to accelerate cell lysis.
[0044] 2) Use a pipette to remove the lysate from step 1) into a clean RNase-Free 1.5 mL centrifuge tube and let it stand at room temperature for 5 minutes.
[0045] 3) Add 250 μL of chloroform, shake the test tube vigorously for about 15 seconds, and let it stand at room temperature for 5 minutes.
[0046] 4) Centrifuge at 10,000 rpm for 10 min at 4°C.
[0047] 5) Carefully remove the aqueous phase with a pipette. Leave some of the aqueous phase (about 1 mm above the DNA layer to prevent DNA contamination) in another 1.5 mL centrifuge tube.
[0048] 6) Add an equal volume of isopropanol, mix gently, and let stand at room temperature for 5 minutes.
[0049] 7) Centrifuge at 4°C, 14,000 rpm for 20 min, discard the supernatant, add 0.5 ml of 75% ethanol, and mix again.
[0050] 8) Centrifuge at 13,000 rpm for 10 min at 4°C and discard the supernatant.
[0051] 9) Centrifuge at low speed and discard the residual liquid, add 20 μl RNase-Free water to fully dissolve the precipitate.
[0052] 3. Total RNA quantification and purity analysis
[0053] The optical density of RNA at 260 nm and 280 nm was measured using a UV spectrophotometer. 260 / OD 280 The purity of RNA is considered reliable within the range of 1.8-2.0.
[0054] 4. RT-qPCR method was used to verify the expression difference of SLC2A3 in gastric cancer and adjacent tissues
[0055] 4.1 Reverse transcription reaction
[0056] The reaction system is shown in Table 1:
[0057] Table 1 Reverse transcription reaction system
[0058]
[0059] The reaction conditions are: 37°C, 15 min; 85°C, 5 s; 4°C, the reaction is over. The product cDNA is used for the next step or stored at -20°C.
[0060] 4.2 Primer synthesis and design
[0061] The primer sequences used in the SLC2A3 content determination process are shown in Table 2:
[0062] Table 2 Summary of SLC2A3 primer sequences
[0063]
[0064] 4.3qPCR reaction
[0065] The reaction system is shown in Table 3:
[0066] Table 3 RT-PCR reaction system
[0067]
[0068] The reaction conditions were: 95°C, 30 s; 95°C, 5 s; 60°C, 30 s; 72°C, 30 s; for a total of 45 cycles.
[0069] 4.4 Statistical analysis
[0070] All experiments were repeated three times, and the data were processed by SPSS16.0 and expressed as mean ± standard deviation. The paired comparison between cancer and adjacent tissues was performed by t-test, and statistical differences were considered when p < 0.05.
[0071] 4.5 Results
[0072] The results are as follows Figure 1 , 2 As shown in the results, the expression level of SLC2A3 gene in gastric cancer tissues was higher than that in normal tissues; compared with gastric mucosal epithelial cells, the expression level of SLC2A3 in gastric cancer cell lines Fu97 and MGC803 was significantly upregulated, and the difference was statistically significant (P<0.05).
[0073] 2. Suppression of SLC2A3 expression
[0074] 1. Cell culture
[0075] The specific steps are the same as those in Example 1.
[0076] 2. Design of siRNA
[0077] Three siRNAs for SLC2A3 were designed using an online siRNA design tool: #1 , SEQ ID NO.3 (tgtcactggtggctgctttat); siRNA #2 , SEQ ID NO.4 (ccttcctgctatcctacaaag) and siRNA #3 , SEQ ID NO. 5 (ccctccgctgctcactattta).
[0078] 3. Transfection
[0079] Gastric cancer cell HGC27 was divided into four groups: blank control group (transfected with meaningless siRNA), siRNA group #1 (Transfection of siRNA #1 ), siRNA group #2 (Transfection of siRNA #2 ) and siRNA group #3 (Transfection of siRNA #3 ).
[0080] The siRNA concentration was 50 nM. The medium was changed 24 hours after transfection, and 72 hours later, 20 ug / ml concentration of puromycin was used to act on the virus-transfected cells for 3 days to screen out cells that were successfully transfected with the virus.
[0081] 4. Total RNA extraction and SLC2A3 expression detection and analysis
[0082] After 72 hours, the cell samples were collected, and the subsequent specific steps were the same as those in Example 1.
[0083] 5. Results
[0084] like Figure 3 As shown, compared with the control group, transfection with specific siRNA#1 The SLC2A3 in the 2 groups was significantly downregulated, and the difference was statistically significant (P<0.05). #2 Group- and transfection-specific siRNA #3 SLC2A3 in the WT and WT groups was not significantly downregulated.
[0085] 3. Downregulation of SLC2A3 expression can significantly inhibit the migration ability of gastric cancer cells
[0086] The Transwell method was used to detect the effect of SLC2A3 on the metastatic ability of gastric cancer cells. The steps are as follows:
[0087] (1) The cell culture and transfection steps are the same as in Example 2.
[0088] (2) Take a 24-well plate, add 800 μl of DMEM containing serum to the bottom of each of the 6 wells, and then place the 6 chambers into the 24-well plate.
[0089] (3) The cells in each group were digested with trypsin and resuspended (after trypsin digestion, the digestion was terminated with serum-containing DMEM, and the cells were resuspended with serum-free DMEM), counted, and the cell concentration was adjusted to 1×10 per well. 5 A total of 100 cells were inoculated into the chamber with gastric cancer cells HGC27. Three duplicate wells were set up for each group of cells, with 200ul in each well.
[0090] (4) Finally, place the chamber and the 24-well plate into an incubator for 24 hours.
[0091] (5) Take out the chamber from the 24-well plate, discard the culture medium in the chamber, add paraformaldehyde fixative and fix for 30 minutes. Discard the paraformaldehyde, rinse the chamber with PBS, add crystal violet to the chamber for dyeing, and transfer the chamber to the 24-well plate with crystal violet so that the inside and outside of the chamber are immersed in crystal violet and dye for 30 minutes.
[0092] (6) Discard the crystal violet and slowly rinse the inside and outside of the chamber with water. After washing, gently wipe the inside of the chamber with a cotton swab. Turn the chamber upside down and let it air dry naturally. Finally, observe the cell migration on the back of the chamber under a microscope.
[0093] (7) Results
[0094] The results are as follows Figure 4 As shown, compared with the control group, the cell migration ability of the SLC2A3 gene knockdown group was significantly inhibited.
[0095] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. Application of SLC2A3 in the preparation of diagnostic reagents or diagnostic kits for gastric cancer peritoneal metastasis.
2. The use according to claim 1, characterized in that: The diagnostic reagent is a reagent for detecting the content of SLC2A3 in a biological sample, and the diagnostic kit comprises a reagent for detecting the content of SLC2A3 in a biological sample.
3. The use according to claim 2, characterized in that: The reagent for detecting the content of SLC2A3 in a biological sample is selected from PCR primers with detection specificity for SLC2A3, and the nucleic acid sequence of the PCR primers is shown in SEQ ID NO.1-2.
4. The use according to claim 2, characterized in that: The biological sample is selected from gastric cancer tissue.
5. A diagnostic kit for gastric cancer or gastric cancer peritoneal metastasis, the kit comprising a reagent for detecting the content of SLC2A3 in a biological sample.
6. The diagnostic kit according to claim 5, characterized in that The diagnostic kit is composed of a reverse transcription system, a primer system and an amplification system. The primer system includes PCR primers as shown in SEQ ID NO.1-2.
7. Use of an agent that inhibits or silences SLC2A3 expression in the preparation of a drug for treating gastric cancer.
8. The use according to claim 7, characterized in that: The drug is an interfering RNA of SLC2A3, and its sequence is shown in any one of SEQ ID NOs. 3 to 5.
9. A pharmaceutical composition for treating gastric cancer, characterized in that: The invention comprises active components and pharmaceutically acceptable excipients, wherein the active components are selected from interfering RNA of SLC2A3, and the sequence thereof is shown in any one of SEQ ID NOs. 3 to 5.
Citation Information
Patent Citations
Scoring model for predicting stomach cancer prognosis and adjuvant chemotherapy benefit risk, construction method and application
CN117238502A
Utilization to diagnosis of gastric cancer, and drug discovery by identification of high gastric cancer-expressing gene
JP2008118915A
